Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 213

Similar articles for PubMed (Select 22544507)

1.

Molecular therapies for tuberous sclerosis and neurofibromatosis.

Franz DN, Weiss BD.

Curr Neurol Neurosci Rep. 2012 Jun;12(3):294-301. doi: 10.1007/s11910-012-0269-4. Review.

PMID:
22544507
2.
3.

Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.

Franz DN.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1181-92. doi: 10.1586/era.11.93. Review.

PMID:
21916571
4.

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.

Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J.

Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94. Epub 2004 Sep 1.

5.

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.

Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6. Epub 2002 Sep 23.

6.

Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.

Budde K, Gaedeke J.

Am J Kidney Dis. 2012 Feb;59(2):276-83. doi: 10.1053/j.ajkd.2011.10.013. Epub 2011 Nov 29. Review.

PMID:
22130643
7.

A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.

Feliciano DM, Lin TV, Hartman NW, Bartley CM, Kubera C, Hsieh L, Lafourcade C, O'Keefe RA, Bordey A.

Int J Dev Neurosci. 2013 Nov;31(7):667-78. doi: 10.1016/j.ijdevneu.2013.02.008. Epub 2013 Feb 26. Review.

8.

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.

Mi R, Ma J, Zhang D, Li L, Zhang H.

J Genet Genomics. 2009 Jun;36(6):355-61. doi: 10.1016/S1673-8527(08)60124-1.

PMID:
19539245
9.

Missense mutations to the TSC1 gene cause tuberous sclerosis complex.

Nellist M, van den Heuvel D, Schluep D, Exalto C, Goedbloed M, Maat-Kievit A, van Essen T, van Spaendonck-Zwarts K, Jansen F, Helderman P, Bartalini G, Vierimaa O, Penttinen M, van den Ende J, van den Ouweland A, Halley D.

Eur J Hum Genet. 2009 Mar;17(3):319-28. doi: 10.1038/ejhg.2008.170. Epub 2008 Oct 1.

10.

Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.

Tyburczy ME, Kotulska K, Pokarowski P, Mieczkowski J, Kucharska J, Grajkowska W, Roszkowski M, Jozwiak S, Kaminska B.

Am J Pathol. 2010 Apr;176(4):1878-90. doi: 10.2353/ajpath.2010.090950. Epub 2010 Feb 4.

11.
12.

Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis.

Neuman NA, Henske EP.

EMBO Mol Med. 2011 Apr;3(4):189-200. doi: 10.1002/emmm.201100131. Epub 2011 Mar 16. Review.

13.

Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.

Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ.

J Neuropathol Exp Neurol. 2004 Dec;63(12):1236-42.

PMID:
15624760
14.

Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Moavero R, Coniglio A, Garaci F, Curatolo P.

Ital J Pediatr. 2013 Sep 17;39:57. doi: 10.1186/1824-7288-39-57. Review.

15.

Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment.

Inoki K, Guan KL.

Hum Mol Genet. 2009 Apr 15;18(R1):R94-100. doi: 10.1093/hmg/ddp032. Review.

16.

Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.

Kwiatkowski DJ, Manning BD.

Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R251-8. Review.

17.

Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.

Astrinidis A, Henske EP.

Oncogene. 2005 Nov 14;24(50):7475-81. Review.

PMID:
16288294
18.

Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.

Gottfried ON, Viskochil DH, Couldwell WT.

Neurosurg Focus. 2010 Jan;28(1):E8. doi: 10.3171/2009.11.FOCUS09221.

PMID:
20043723
19.

The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas.

Plank TL, Logginidou H, Klein-Szanto A, Henske EP.

Mod Pathol. 1999 May;12(5):539-45.

PMID:
10349994
20.

Possible prevention of tuberous sclerosis complex lesions.

Kotulska K, Borkowska J, Jozwiak S.

Pediatrics. 2013 Jul;132(1):e239-42. doi: 10.1542/peds.2012-3607. Epub 2013 Jun 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk